| Identification | Back Directory | [Name]
1-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)uracil | [CAS]
69123-94-0 | [Synonyms]
FAU
2'-Deoxy-2'-fluoro-beta-D-arabinouridine
2'-Fluoro-2'-deoxy-arabinofuranosyl-uridine
2'-Fluoro-arabinofuranosyl-2'-deoxy-uridine
1,3-Dimethyl-4-Amino-5-Formamide-Uracil FAU
1-(2'-Deoxy-2'-fluoro-b-D-arabinofuranosyl)uracil
2’-fluoro-5-ethyl-1-beta-d-arabinofuranosyluracil
2'-FLUORO 2'-DEOXYURACIL-BETA-D-ARABINOFURANOSIDE
2'-FLUORO-2'-DEOXYURACYL-BETA-D-ARABINOFURANOSIDE
1-(2-DEOXY-2-FLUORO-BETA-D-ARABINOFURANOSYL)URACIL
1-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-uraci
2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-
2,4(1H,3H)-PyriMidinedione, 1-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)-
2,4(1H,3H)-PYRIMIDINEDIONE, 1-(2-DEOXY-2-FLUORO-BETA-D-ARABINOFURANOSYL)
1-[(2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
1-((2R,3S,4R,5R)-3-FLUORO-4-HYDROXY-5-HYDROXYMETHYL-TETRAHYDRO-FURAN-2-YL)-1H-PYRIMIDINE-2,4-DIONE
1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione | [Molecular Formula]
C9H11FN2O5 | [MDL Number]
MFCD00870798 | [MOL File]
69123-94-0.mol | [Molecular Weight]
246.19 |
| Chemical Properties | Back Directory | [Appearance]
Colourless solid | [Melting point ]
162 °C(Solv: chloroform (67-66-3); methanol (67-56-1)) | [density ]
1.63±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
Methanol: Soluble | [form ]
Solid | [pka]
9.39±0.10(Predicted) | [color ]
White to off-white | [InChI]
InChI=1/C9H11FN2O5/c10-6-7(15)4(3-13)17-8(6)12-2-1-5(14)11-9(12)16/h1-2,4,6-8,13,15H,3H2,(H,11,14,16)/t4-,6+,7-,8-/s3 | [InChIKey]
UIYWFOZZIZEEKJ-QOUWCGOQNA-N | [SMILES]
[C@@H]1([C@@H](F)[C@H](O)[C@@H](CO)O1)N1C=CC(=O)NC1=O |&1:0,1,3,5,r| | [CAS DataBase Reference]
69123-94-0 |
| Hazard Information | Back Directory | [Chemical Properties]
Colourless solid | [Uses]
1-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)uracil is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. | [References]
[1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005 |
|
|